ALP Bio utilizes human tonsil-derived immune data alongside advanced AI models to minimize the risk of immunogenicity in drug development.
ALP Bio has raised $187K in total funding. The most recent round was Grant. The last funding was announced in July 2026.
ALP Bio's investors include 42CAP, Venture Kick, Ajira Ventures.
ALP Bio is headquartered in Schlieren, Switzerland.
ALP Bio utilizes human tonsil-derived immune data alongside advanced AI models to minimize the risk of immunogenicity in drug development.
ALP Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ALP Bio — Funding & Investors." VCBacked, July 3, 2026, https://www.vcbacked.co/company/alp-bio. Accessed August 14, 2026.
VCBacked. (2026). ALP Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/alp-bio
{{cite web |title=ALP Bio — Funding & Investors |url=https://www.vcbacked.co/company/alp-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated